Видео ютуба по тегу Ceo Syngene

Syngene International Q1 Results: Profit Falls 19%, Maintains FY25 Guidance
Syngene International Q1 Results: Profit Falls 19%, Maintains FY25 Guidance
Syngene Q1 Earnings: In-Line Profits Recorded, What's The Growth Outlook Of Company In Future?
Syngene Q1 Earnings: In-Line Profits Recorded, What's The Growth Outlook Of Company In Future?
Syngene International Earnings Call - Q2 FY25
Syngene International Earnings Call - Q2 FY25
Q3 Review | Syngene International's Growth Strategies & Projections For 2023| BQ Prime
Q3 Review | Syngene International's Growth Strategies & Projections For 2023| BQ Prime
Biosimilar Growth Is Offsetting Decline In Syngene & Generics: Biocon | CNBC TV18
Biosimilar Growth Is Offsetting Decline In Syngene & Generics: Biocon | CNBC TV18
Syngene International Ltd Q2 FY2024-25 Earnings Conference Call
Syngene International Ltd Q2 FY2024-25 Earnings Conference Call
Syngene International Ltd Q2 FY24 Earnings Concall
Syngene International Ltd Q2 FY24 Earnings Concall
Syngene International Q2: Profit Shrinks & Margins Narrow, CEO Jonathan Hunt On Growth Outlook
Syngene International Q2: Profit Shrinks & Margins Narrow, CEO Jonathan Hunt On Growth Outlook
Syngene International Earnings Call - Q3 FY25
Syngene International Earnings Call - Q3 FY25
Syngene CEO Jonathan Hunt On Guidance Upgrade
Syngene CEO Jonathan Hunt On Guidance Upgrade
Syngene International In-Line Q2 Result: Key Growth Drivers, Margin Guidance Ahead | Jonathan Hunt
Syngene International In-Line Q2 Result: Key Growth Drivers, Margin Guidance Ahead | Jonathan Hunt
Syngene International Ltd Q3 FY23 Earnings Concall
Syngene International Ltd Q3 FY23 Earnings Concall
Syngene International Ltd Q1 FY23 Earnings Concall
Syngene International Ltd Q1 FY23 Earnings Concall
Syngene International Q3 Fineprint, Capex Focus & FY25 Growth Drivers | Jonathan Hunt
Syngene International Q3 Fineprint, Capex Focus & FY25 Growth Drivers | Jonathan Hunt
Expect Biologics To Take Off In The Next 18 Months: Syngene International | CNBC TV18
Expect Biologics To Take Off In The Next 18 Months: Syngene International | CNBC TV18
Syngene's Q3 Revenue To Grow In Discovery And Development Services: CEO
Syngene's Q3 Revenue To Grow In Discovery And Development Services: CEO
SYNGENE Stock | Syngene International Ltd Q2 FY23 Earnings Concall
SYNGENE Stock | Syngene International Ltd Q2 FY23 Earnings Concall
Обзор первого квартала | Управляющий директор и генеральный директор Syngene поделился прогнозом на 23 финансовый год
Обзор первого квартала | Управляющий директор и генеральный директор Syngene поделился прогнозом на 23 финансовый год
Strong Show From Syngene In Q2 | MD & CEO Jonathan Hunt | Business News
Strong Show From Syngene In Q2 | MD & CEO Jonathan Hunt | Business News
Табель успеваемости за 4 квартал и прогноз роста с генеральным директором Syngene
Табель успеваемости за 4 квартал и прогноз роста с генеральным директором Syngene